Rethinking the initial changes in subarachnoid haemorrhage: Focusing on real-time metabolism during early brain injury

Yujie Chen,a,b,** Ian Galea,c R. Loch Macdonald,d George Kwok Chu Wong,e and John H. Zhangf,g*

aDepartment of Neurosurgery and State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China
bCAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
cClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
dCommunity Neurosciences Institutes, Community Regional Medical Center, Fresno, CA 93701, USA
eDivision of Neurosurgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong 999077, China
fNeuroscience Research Center, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
gDepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA

Summary

Over the last two decades, neurological researchers have uncovered many pathophysiological mechanisms associated with subarachnoid haemorrhage (SAH), with early brain injury and delayed cerebral ischaemia both contributing to morbidity and mortality. The current dilemma in SAH management inspired us to rethink the nature of the insult in SAH: sudden bleeding into the subarachnoid space and hypoxia due to disturbed cerebral circulation and increased intracranial pressure, generating exogenous stimuli and subsequent pathophysiological processes. Exogenous stimuli are defined as factors which the brain tissue is not normally exposed to when in the healthy state. Intersections of these initial pathogenic factors lead to secondary brain injury with related metabolic changes after SAH. Herein, we summarized the current understanding of efforts to monitor and analyse SAH-related metabolic changes to identify those precise pathophysiological processes and potential therapeutic strategies; in particular, we highlight the restoration of normal cerebrospinal fluid circulation and the normalization of brain-blood interface physiology to alleviate early brain injury and delayed neurological deterioration after SAH.

Introduction

Subarachnoid haemorrhage (SAH) is an acute cerebrovascular disorder and is mainly caused by rupture of intracranial aneurysms. Although ruptured aneurysms can be effectively treated by surgical clamping or interventional embolization, the inpatient mortality for patients with ruptured aneurysms has remained unchanged in the United States, ranging from 13.7% in 2006 to 13.1% in 2018.1 In recent years, the milestone CONSCIOUS-2 (NCT00558311) and CONSCIOUS-3 (NCT00940095) clinical trials have inspired us to focus on early brain injury, in addition to delayed cerebral ischaemia caused by vasospasm after SAH.2 However, there is still a lack of in-depth understanding and effective treatment of secondary brain injury, which leads to a poor prognosis in patients with SAH, often including cognitive dysfunction.3

Current theory in SAH research and management includes consideration of the two distinct physiological insults that occur immediately after SAH: 1) sudden bleeding into the subarachnoid space and 2) hypoxia due to disturbed cerebral circulation and increased intracranial pressure. Early brain injury may follow
Intersections in the pathophysiological changes induced by two initial factors

Exogenous stimuli in CSF induce microcirculatory dysfunction (Figure 1)

It is well known that the CSF circulation helps maintain brain haemostasis and normal metabolism. Sudden bleeding into the subarachnoid space could cause disruption of flow in the cerebral ventricles, along perivascular spaces and the glymphatic system by the exogenous stimuli mentioned above. Several decades of experimental and clinical data indicate that CSF haemoglobin induces secondary brain injury after SAH, as we speculated before. Targeting CSF haemoglobin reduces delayed cerebral ischaemia and improves neurological outcomes after SAH in animal models and has potential for clinical application in patients.

However, there are not just blood and haemolytic products in CSF; at least two types of materials should be specifically considered and monitored. One is haemolytic product-induced secondary neuroinflammatory factors, such as inflammasome-derived caspase-1 activity, which is tightly associated with blood coagulation in CSF and poor prognosis of SAH patients.

Elevated CSF lipocalin-2 mediates neuroinflammation and iron homeostasis and is reported to be a biomarker for unfavourable outcomes of SAH patients and a potential therapeutic target for long-term neurological rehabilitation.

Another set of biomarkers comprises the brain metabolites released into CSF, which could serve as biomarkers of brain injury by exogenous stimuli and, more importantly, as the initiators of secondary brain injury that eventually leads to irreversible pathophysiologic cascades. Ho WM et al. employed a validated kit to identify and quantify 186 endogenous metabolites in the CSF sample of SAH patients and surprisingly found no significant changes in glutamate, creatinine and several other metabolomics in CSF within 24 hrs after SAH, but taurine levels significantly decreased, and 17 amino acids, including glutamate and creatinine, substantially increased and reached a maximum 1 week after SAH. Wang KC et al. reported that high mobility group box 1 (HMGB1) released by injured neurons into the CSF also participates in subsequent immune responses and serves as a prognostic indicator for SAH patients.

Therefore, time-dependent alterations in CSF metabolites and compounds may elucidate pathophysiologic processes after SAH, and machine learning-driven metabolomic evaluation of CSF might provide more in-depth information on the pathologic underpinnings of secondary brain injury after SAH.

Figure 1. Schematic diagram of the microcirculation dysfunction induced by initial stimulation after SAH.

Left: Schematic diagram of the normal cerebral microcirculation. Right: Schematic diagram of microcirculation disturbance after SAH. After microvasospasms in the compensation period, platelet aggregation and leukocyte plugging in capillaries cause microcirculation dysfunction in the decompensation phase. When the microthrombi fill microvessels and the glymphatic drainage system, the whole microcirculation collapses without blood flow, and microcirculation dysfunction moves into an irreversible phase.
During aneurysm clipping surgery, Uhl et al. observed monosegmental and pearl-string multisegmental microvasospasms in arterioles for the first time, with a 75% reduction in cortical microcirculation after SAH. A recent digital subtraction angiography (DSA) study found that the intracerebral circulation time within 24 hrs after ictus was significantly correlated with the occurrence of delayed cerebral ischaemia in SAH patients as an independent factor in addition to angiographic vasospasm, which suggests that microcirculatory dysfunction in the ultra-early and subacute phases can be a causative factor for delayed cerebral ischaemia development and poor outcome.

More importantly, these microvasospasms in arterioles are not mediated by endothelin A receptors, suggesting distinct mechanisms in large and small cerebral vessels, which might be an explanation for the unfavorable results of CONSCIOUS trials. Our previous study demonstrated that haemoglobin induced acute pericapillary pericyte contraction, resulting in vivid and similar pearl-string-like microvasospasms for microcirculation dysfunction after SAH in mice. Haem degradation intermediate bilirubin oxidation end products (BOXes) and propentidypents (PDPs) are significantly abundant in the CSF of patients with SAH and exhibit vasoconstrictive effects contributing to neurological deficits. In addition, free iron (Fe3+) released from haemolytic red blood cells is also involved in arteriolar and capillary microvasospasms after SAH in mice, while iron deposits in the cortex have been reported to be associated with cognitive outcomes in SAH patients.

As we previously proposed and reviewed, there are three steps of microcirculation disturbance after SAH: microcirculation compensation, decompensation and irreversible phases. After microvasospasms in the compensation period, platelet aggregation and leukocyte plugging in capillaries cause microcirculation dysfunction after SAH in mice. Haem degradation intermediate bilirubin oxidation end products (BOXes) and propentidypents (PDPs) are significantly abundant in the CSF of patients with SAH and exhibit vasoconstrictive effects contributing to neurological deficits. In addition, free iron (Fe3+) released from haemolytic red blood cells is also involved in arteriolar and capillary microvasospasms after SAH in mice, while iron deposits in the cortex have been reported to be associated with cognitive outcomes in SAH patients.

As we previously proposed and reviewed, there are three steps of microcirculation disturbance after SAH: microcirculation compensation, decompensation and irreversible phases. After microvasospasms in the compensation period, platelet aggregation and leukocyte plugging in capillaries cause microcirculation dysfunction after SAH in mice. Haem degradation intermediate bilirubin oxidation end products (BOXes) and propentidypents (PDPs) are significantly abundant in the CSF of patients with SAH and exhibit vasoconstrictive effects contributing to neurological deficits. In addition, free iron (Fe3+) released from haemolytic red blood cells is also involved in arteriolar and capillary microvasospasms after SAH in mice, while iron deposits in the cortex have been reported to be associated with cognitive outcomes in SAH patients.

Hypoxia aggravates pathophysiological changes after bleeding into the CSF

It is well known that the vast majority of patients lack ischaemic lesions in brain imaging at the early phase of SAH; even in limited cohorts with poor-grade ruptured aneurysms, only approximately 21% of patients suffer from cerebral infarction. However, the metabolomic profiling of CSF indicates that 2-hydroxylglutarate, a known marker of tissue hypoxia, correlates with the long-term outcomes of SAH patients independent of vasospasm status. Cerebral microdialysis and multimodal neuromonitoring strategies have found that brain tissue hypoxia (PbtO2 < 20 mmHg) exists in more than 60% of patients within the first 24 h after SAH.

During brain hypoxia, hypoxia-inducible factor-1α (HIF-1α) is traditionally considered to be the core of pathophysiological processes. Accumulated evidence has established the dual nature of HIF-1α as an adaptive factor and cell death mediator, which depends on pathophysiological conditions, developmental phase, comorbidities, and administered medications. Dong Y et al. inhibited HIF-1α using YC-1 and found increased hippocampal apoptosis and cognitive dysfunction, while 2-methoxyestradiol, acting as a HIF-1α inhibitor, ameliorated early brain injury and cerebral vasospasm in SAH rats. There are two principal ways by which HIF-1α is activated: an oxygen-dependent reaction and an oxygen-independent reaction. Hypoxia and oxidizing redox status are considered established enhancers of HIF-1α protein stabilization, while nonhypoxic activators appear to include only HIF-1α activity and not protein stabilization. Normoxia and several protein modifications decrease HIF-1α expression and activity. HIF-1α not only regulates the expression of target genes and thereby influences resultant protein levels but also contributes to epigenetic changes that may reciprocally provide feedback regulation loops. On this basis, we wondered whether there are more comprehensive pathophysiological changes underlying brain hypoxia after SAH. Lactate in CSF, as the intermediate product of the tricarboxylic acid cycle and energy metabolism, has been demonstrated to be a biomarker for early brain injury and tightly correlated with neurological outcomes in SAH patients. Therefore, assessment of the lactate/pyruvate ratio in dialysate obtained as part of multimodal monitoring during early brain injury might be informative and beneficial for SAH patients. The underlying mechanism of lactate-mediated pathophysiological processes might be much more complicated than previously thought. In addition to acting as a biomarker secondary to metabolomic production under hypoxia, lactate may be a pathogenic mediator, as it can regulate downstream gene expression by lactylation of histones and of nonhistone proteins, a newly reported posttranslational modification. Despite limited evidence of the role and mechanism of lactylation, repeated lactate exposure has major effects on the expression of regulatory enzymes of glycolysis and mitochondrial respiration. It has been demonstrated that lysine lactylation in brain macrophages is regulated by neural excitation and social stress, with parallel changes in lactate levels. Histone lactylation might occur separately from interleukin-6-
induced inflammatory metabolic adaptation. Thus, targeting lactylation may be a potential therapeutic approach for cancer, inflammation, Alzheimer’s disease and other brain disorders.

Advances in monitoring metabolomic changes associated with early brain injury after SAH

Ideally, the goal of neurocritical care management for SAH and other acute brain injuries is to restore effective oxygen and glucose delivery to the brain, which typically requires adequate intracranial vascular perfusion; thus, therapeutic hypervolaemia, haemodilution, and hypertension (HHH) therapy has been used for SAH patients for a long time. A recent study indicated that although global and regional cerebral blood flow improved with HHH therapy, metabolites in microdialysis fluid were statistically unchanged in SAH patients. In this cohort, no patients exhibited signs of severe ischaemia but they commonly had a disturbed energy metabolic pattern, possibly reflecting mitochondrial dysfunction in addition to improved microcirculation. Extracellular mitochondria in CSF may provide additional information on brain integrity and recovery after SAH. Thus, mitochondrial dysfunction could be a potential therapeutic target for SAH management, but further studies are needed to precisely evaluate the spatial variations and characterize the biological cascade.

Spatial metabolomics to assess real-time metabolic changes (Figure 2)

Although SAH usually has a specific causative factor, complex primary injury is superimposed on the patient’s own susceptibility factors, resulting in multiple interwoven pathophysiological changes along the time sequence. A large amount of biological information and biomarkers can be used in clinical diagnosis and treatment. In addition to neuroimaging and electrophysiological monitoring, metabolic biomarker measurement reflects the real-time changes in brain injury lesions on another level, especially the occurrence, development and outcome of secondary brain injury after SAH; together, these three techniques constitute a multimodal monitoring system to capture the larger picture of SAH pathophysiology. Thus, in contrast to the previous monitoring and clinical validation of a single indicator, multiple indicators, or even a spectrum of biomarker expression, in the search for and systematic study of biomarkers closely related to the pathophysiological mechanism of brain injury could be a technical roadmap for future SAH research, similar to the five-phase framework for developing epileptogenic biomarkers. Interestingly, recent analysis indicates that biomarkers within 24 hrs after acute brain injury are related to the severity of injury rather than the pathoanatomical type of injury, including SAH.

Unlike traditional proteomic and metabolomic analyses of biological samples harvested from human patients or experimental animal models, high-spatial-resolution imaging mass spectrometry-based spatial metabolomics can visualize the composition, abundance, and spatial distribution of molecules in tissues or cells and has been widely used in life science research. Recently, Chen Y et al. employed matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to visualize the spatial-chemical changes in metabolite concentrations in an APP/PS1

![Figure 2. Schematic diagram of the different levels of metabolic changes in the brain parenchyma after SAH.](https://www.thelancet.com Vol 83 September, 2022)
transgenic mouse model of Alzheimer’s disease and found 93 metabolites within different brain regions linked to the etiopathogenesis of Alzheimer’s disease.\textsuperscript{53} This newly adopted technology might have applications in scenarios lacking reliable immunohistochemical and diagnostic biomarkers\textsuperscript{54} for real-time metabolic changes in the brain parenchyma. In addition, extended algorithms, such as false discovery rate (FDR)-controlled metabolite annotation\textsuperscript{55} or the spatial single nuclear metabolomics (SEAM) platform,\textsuperscript{56} could explore the spatial metabolic profile and tissue histology at the single-cell level, leading to a deeper understanding of tissue metabolic organization.

**Cascade biomarkers and comparative proteomics analysis of early brain injury in SAH patients (Figure 3)**

Blood circulation runs through all tissues and organs of the body, and therefore clinical biomarkers are commonly assayed in blood. The correlation of peripheral blood NF-L, GFAP, Tau and other biomarkers with brain injury and prognosis after SAH has been widely recognized.\textsuperscript{57–59} Grant C. O’Connell’s team enrolled nearly 12,000 human specimens to evaluate over 17,000 protein-coding genes and developed algorithms to investigate their potential to produce blood biomarkers for neurological damage based on their expression profiles both across the body and within the brain;\textsuperscript{60} this valuable resource is expected to be applied for advancing clinical diagnosis and treatment of acute and chronic central nervous system diseases such as traumatic brain injury, ischaemic or haemorrhagic stroke, Alzheimer’s disease and multiple sclerosis.

CSF, as one of the intrinsic components of the intracranial system, is wrapped around and supports the whole brain and spinal cord and plays a role in supporting and removing metabolic products, which contain a variety of signals that participate in regulating the activities of the central nervous system, as well as brain tissue metabolites and the exchange of materials with the blood. Although CSF is connected with the blood circulation through the interstitial perivascular drainage pathway, the glymphatic system and peripheral lymphatic vessels in the brain,\textsuperscript{61,62} it is a relatively closed system. Compared with blood biomarkers, CSF biomarkers can directly reflect brain tissue injury and metabolism after traumatic brain injury. Since the beginning of the 21st century, CSF biomarkers associated with secondary brain injury after SAH have gradually gained attention, especially low abundance proteins specific to CSF, making important progress in the diagnosis and monitoring of early brain injury and prognostication.\textsuperscript{29,63}

![Figure 3. Cascade connections of various biomarkers to monitor early brain injury after SAH.](https://example.com/cascadeConnections.png)
In addition, easily accessible body fluids such as urine, saliva and tears may have unimaginable practical value in clinical service environments where there are no monitoring facilities for brain injury. Cortisol remains the only biomarker that can be detected in blood, CSF, urine and saliva. MicroRNA and Apo-lipoprotein E are salivary biomarkers, and S100β and nor-epinephrine can be monitored in urine, according to a large systematic review. The development of biomarkers based on the biological metabolic cascade system of brain injury, where metabolite changes in the brain or subarachnoid space are reflected in the CSF, and then in blood, urine and saliva, has potential for enable a future breakthrough in the field of rapid, non-invasive, on-site diagnostics for brain injury.

Comparative proteomics evaluates metabolic changes or differences in all protein expression levels in suborganellar targets, cells, tissues, and biofluids under different conditions. Thus, multiple biological samples from SAH patients and animal models might provide a more systematic understanding of secondary brain injury after SAH (Table 1). Recently, Andrew A. Pieper’s research team analysed ac-Tau from four different angles: ac-Tau production induced by brain injury, plasma ac-Tau marker monitoring, neuroprotective mechanism of ac-Tau inhibition, and ac-Tau-induced encephalopathy after brain injury. This study provided an in-depth view of the role and mechanism of ac-Tau in the pathophysiological process of brain trauma and its prospects for application as a biomarker, which could serve as an excellent example for the development of biomarkers for brain trauma and other central nervous system diseases and for further translational clinical practice.

Implications for the mechanism and therapeutic strategies of SAH

Restoring the balance of CSF circulation

As summarized above, exogenous stimuli in the CSF induce cerebral circulation dysfunction after SAH, while brain metabolites are secreted into the interstitial fluid and CSF, acting as both biomarkers and pathogenic factors. The unclear visible components of the blood appear as blood clots in the sulci and cisterns, and block the normal flow of CSF, further increasing the intracranial pressure. The balance between CSF pressure and precapillary and venous pressure is unbalanced and the volume of fluid in the brain is further increased. In addition, hindrance of CSF circulation along lymphatic pathways is another mechanism that may interrupt the drainage of damaging substances from the subarachnoid space and parenchyma because a recent finding of CSF flow block did not correlate with the size of haemorrhage, while CSF macrophage CD163, a haemoglobin scavenger receptor for blood clearance, was significantly associated with hydrocephalus and outcome after SAH in patients. Moreover, meningeal lymphatics also participate in clearing red blood cells from the CSF to cervical lymph nodes without significant lymphangiogenesis and lymphangiectasia in SAH mice. Despite the effectiveness of CSF external drainage strategies, the average output of CSF after SAH is a risk factor for vasospasm and chronic hydrocephalus, and CSF volume based on algorithm-assisted segmentation of computed tomography images might be a surrogate for vasospasm after SAH. Therefore, restoring CSF circulation balance after SAH is beneficial not only for the overall clinical outcome of SAH patients but also for obtaining more precise information on both destructive stimuli and metabolites from microdialysis fluid and CSF to enable advances in vascular neural network protection and neurological recovery.

Reconstruction of intracranial barrier structures

The blood-brain barrier (BBB) is an endogenous protective structure for brain haemostasis and normal metabolism. However, SAH induces serious alterations in component cells, leading to brain homeostasis disruption. It was reported that most SAH patients lack imaging lesions of brain parenchymal injury but have significant BBB disruption, which occurs immediately after SAH but has long-lasting consequences. Early detection of BBB dysfunction could effectively predict neurological outcomes after SAH, with an area under the receiver operating characteristic curve of 0.829, in combination with the Rosen-Macdonald score. Recent experiments have discovered several pathophysiological mechanisms that effect the BBB after SAH, and alleviating these cascades might be decisive in inhibiting the negative impact of bleeding in the subarachnoid space. Free haem, released through haemolysis, is bound by haemopexin and rapidly scavenged by CD91. It was reported that CSF haemopexin significantly increased and was associated with iron deposition in brain tissue and poorer neurological outcome in SAH patients, and more interestingly, the serum haemopexin level was lower when the BBB was compromised after SAH. Thus, recovery of endogenous recovery mechanisms and barriers can break the vicious cycle, maintain brain metabolic haemostasis and eventually alleviate early brain injury after SAH. However, due to limited studies in this research area, further work is needed.

Conclusion

Over the last two decades, neurological researchers have uncovered many pathophysiological mechanisms, including early brain injury and delayed cerebral ischaemia, which may determine neurological outcomes after SAH. Herein, we have reviewed the current
| Metabolic biomarkers | Intrinsic function | Sample types | Time | Main outcome | References |
|---------------------|-------------------|--------------|------|--------------|------------|
| Blood hemolytic-related |                   |              |      |              |            |
| Hemeoyoglobin (Hb)   |                   |              |      |              |            |
| Neuronin (Ngp)       |                   | Serum        | <7 days after SAH | Serum levels significantly elevated in delayed cerebral ischemia patients with a strong association with the cerebral microdialysis parameters and 12-month functional outcome in severe SAH patients | Brain Behav. 2020;10(3):e01547. Stroke. 2019;50(7):1887-90. World Neurosurg. 2018;116(1):346-52. |
| Lipocalin-2 (LCN-2)  |                   | Serum        | <5 days after SAH | Increased LCN-2 levels were associated with a poor functional outcome | J Neuroinflammation. 2020;7(1):33-8. Mol Neurobiol. 2017;52(4):6572-80. Brain Behav. 2020;10(2):e01517. |
| Ficolin-1            |                   | Serum        | <7 days after SAH | Correlated to Hunt Hess score at admission. | Mol Neurobiol. 2019;56(1):57-61. |
| Soluble lectin like oxidized low density lipoprotein receptor-1 (sLOX-1) |                | Serum        | / | Positive association with hemorrhagic severity, appears to have the potential to be a promising predictor of delayed cerebral ischemia after SAH | J Neuroinflammation. 2020;7(1):33-8. Mol Neurobiol. 2017;52(4):6572-80. Brain Behav. 2020;10(2):e01517. |
| M-ficolin            |                   | Serum        | <7 days after SAH | Correlated to Hunt Hess score at admission. | Mol Neurobiol. 2019;56(1):57-61. |
| Soluble growth stimulation expressed gene-2 (SPEG) | Pro-inflammatory chemokine | Plasma | <14 days after SAH | Plasma CCL2 predicts new epileptiform abnormalities, delayed cerebral ischemia, 90-day outcome, and mortality after SAH, independent of clinical and radiographic markers. | Acta Neurol Scand. 2021;143(5):530-7. |
| Ficolin-1            |                   | Serum        | <7 days after SAH | Increased CCL5 levels were associated with higher SAH severity, brain injury severity, and outcome after aSAH. | J Neuroinflammation. 2020;7(1):33-8. Mol Neurobiol. 2017;52(4):6572-80. Brain Behav. 2020;10(2):e01517. |
| Soluble lectin like oxidized low density lipoprotein receptor-1 (sLOX-1) |                | Serum        | / | Positive association with hemorrhagic severity, appears to have the potential to be a promising predictor of delayed cerebral ischemia after SAH | J Neuroinflammation. 2020;7(1):33-8. Mol Neurobiol. 2017;52(4):6572-80. Brain Behav. 2020;10(2):e01517. |
| M-ficolin            |                   | Serum        | <7 days after SAH | Correlated to Hunt Hess score at admission. | Mol Neurobiol. 2019;56(1):57-61. |
| Soluble growth stimulation expressed gene-2 (SPEG) | Pro-inflammatory chemokine | Plasma | <7 days after SAH | Correlated to Hunt Hess score at admission. | Mol Neurobiol. 2019;56(1):57-61. |
| RhoA                |                   | Peripheral blood mononuclear cells | <5 days after SAH | RhoB expression and activity in peripheral blood mononuclear cells might be related with SAH severity and cerebral vasospasm | Stroke. 2018;49(6):1507-10. |
| Interleukin-33 (IL-33) | Inflammatory cytokine | Serum | On admission | High serum IL-33 concentrations have close relation to the inflammation, severity and poor outcome in aSAH | Clin Chem Acta. 2018;486:214-8. |
| Clusterin             |                   | Serum        | <14 days after SAH | Significant correlation between CCL5 expression and the Glasgow Outcome Scale at 3 months. | World Neurosurg. 2017;107:424-8. |
| Soluble triggering receptor expressed on myeloid cells-1 (STREM-1) | Inflammatory | Serum | <7 days after SAH | Correlations of early CCL5 STREM-1 levels to patients’ severity and prognosis, and Glasgow Outcome Scale at 3 months. | J Clin Neurosci. 2017;35:39-43. |
| Migration inhibitory factor (MIF) | Proinflammatory cytokine | Serum | On admission | Serum MIF provides information about inflammation, brain injury severity and outcome after aSAH | Clin Chim Acta. 2017;473:60-4. |

Table 1 (Continued)
## Table 1 (Continued)

| Metabolic biomarkers                  | Intrinsic function                                      | Sample types | Time             | Main outcome                                                                 | References                                                                  |
|---------------------------------------|----------------------------------------------------------|--------------|------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Vascular-related                      |                                                          |              |                  |                                                                             |                                                                            |
| L-arginine to L-ornithine ratio       | Enzyme arginase-1 is released into CSF during red blood cell lysis and contributes to dysregulated metabolism of the nitric oxide pathway L-arginine | CSF          | <22 days after SAH | Arg/Orn ≥ 2.71 at SAH onset predicted cerebral vasospasm with a sensitivity of 86.7% and specificity of 72.2%. Arg/Orn > 2.71 predicted excellent functional outcome. | Transl Stroke Res. 2022;11(3):382-90. Clinical Trial No. DRR000015293          |
| 2.71 at SAH                           |                                                          |              |                  |                                                                             |                                                                            |
| Arg/Orn                               |                                                          |              |                  |                                                                             |                                                                            |
| CSF / SDMA, DMGV, and Ornithine associate with poor mRS at discharge and at 90d after SAH |                                                          |              |                  |                                                                             |                                                                            |
| Neurons under oxidative stress        |                                                          |              |                  |                                                                             |                                                                            |
| Vasodilatory                          |                                                          |              |                  |                                                                             |                                                                            |
| Calcitonin gene-related peptide (CGRP) |                                                          |              |                  |                                                                             |                                                                            |
| Soluble vascular endothelial-cadherin (sVE-cadherin) | Released from injured endothelium | CSF          | <8 days after SAH | Develop worse functional outcome at 3 months after SAH                      | Neurology. 2020;94(12):e1281-e93.                                          |
| Tissue kallikrein (TK)                | Serine proteases, component of the kallikrein-kinin system | Serum        | /                |                                                                             |                                                                            |
| Lipoprotein-associated phospholipase A2 (lpla2) | Chronic vascular inflammation | Serum        | <24 hours after SAH | Highly correlated with hematologic severity. Independent predictor for delayed cerebral ischemia. Elevated lpla2 level have higher risk of vasospasm and 6-month mortality | Neurosurgery. 2020;46(3):122-31.                                              |
| Hypoxia-related                       |                                                          |              |                  |                                                                             |                                                                            |
| Lactate                              | Hypoxia                                                  | CSF          | <14 days after SAH | Reflect the early brain injury and represent predictive biomarkers of delayed cerebral ischemia following SAH | J Stroke Cerebrovasc Dis. 2020;29(5):104765.                                 |
| Pyruvate                             | Hypoxia                                                  | CSF          | <14 days after SAH | Reflect the early brain injury and represent predictive biomarkers of delayed cerebral ischemia following SAH | J Stroke Cerebrovasc Dis. 2020;29(5):104765.                                 |
| 2-hydroxybutyrate                     | Marker of tissue hypoxia                                 | CSF          | On admission and the anticipated vasospasm timeframe | Correlated with GOS at 1 year post-SAH independent of vasospasm status | Br J Neurosurg. 2018;32(6):337-41.                                            |
| 8-isoprostaglandin F2alpha (8-iso PGF2alpha) | Oxidative stress | Plasma       | On admission     | Plasma 8-iso PGF2alpha elevation associates with the severity and poor outcome after SAH | Clin Chim Acta. 2017;469:166-70.                                             |
| Extracellular mitochondria            | Intracellular metabolic integrity                        | CSF          | <3 days after SAH | Extracellular mitochondria may provide a biomarker-like glimpse into brain injury and recovery after injury | Stroke. 2017;48(8):2231-7.                                                   |
| Neurofilament Light Chain (NfL)      | Neuron injury                                            | Serum        | <3 days after SAH | NFL levels are associated with disease severity during the early brain injury phase of SAH. Higher NFL levels during early brain injury are associated with poor functional outcome on day 30 after ictus and increased mortality rate. | Transl Stroke Res. 2020;11(6):671-7.                                         |
| Serum                                |                                                         | CSF          | <3 days after SAH | NFL levels are associated with disease severity during the early brain injury phase of SAH. Higher NFL levels during early brain injury are associated with poor functional outcome on day 30 after ictus and increased mortality rate. | Transl Stroke Res. 2020;11(6):671-7.                                         |
| sTau/pTau                            | Neuron injury                                            | Serum        | <7 days after SAH | Higher sTau/pTau and lower Abeta40/Abeta42 CSF levels predict unfavorable long-term functional and health-related quality of life outcomes. Neuro-pathologic deficits correlate with increased sTau and pTau concentrations. | Neurosci Res. 2018;12(5):605-14.                                             |
| Abeta40/Abeta42                      |                                                           | Serum        | <7 days after SAH | Higher sTau/pTau and lower Abeta40/Abeta42 CSF levels predict unfavorable long-term functional and health-related quality of life outcomes. Neuro-pathologic deficits correlate with increased sTau and pTau concentrations. | Neurosci Res. 2018;12(5):605-14.                                             |
| Sortilin                             | Enriched in neurons and is likely involved in neurodegenerative diseases. | CSF (Human)  | <3 days after SAH | Sortilin – 100 kDa was detectable in the CSF of the SAH, but not in sham rats. Levels of sortilin – 100 kDa and fragments – 40 kDa in cortical lysates were elevated in the SAH relative to control rats. | Neurosciience. 2021;470:23-36.                                               |
| S100A8/A9( calprotectin)              | Neuron injury                                            | Serum        | <2 days after SAH | Correlated with the clinical severity and the poor prognosis at 3 months in SAH patients | J Stroke Cerebrovasc Dis. 2020;29(5):1247-70.                                |
| Regulated in development and DNA damage responses 1 (REDD1) | Highly conserved stress-response protein and can be induced by hypoxia-ischemia and DNA damage | CSF          | <3 days after SAH | Critical role of neural damage process | Neurosci Res. 2018;12(5):605-14.                                             |
| Nekrin-1                             | Axon guidance molecule                                   | Serum        | /                | Reflects severity, inflammation and prognosis of human aneurysmal SAH         | Clin Chim Acta 2019;499:294-300.                                             |
| Metabolic biomarkers | Intrinsic function | Sample types | Time | Main outcome | References |
|---------------------|--------------------|--------------|------|--------------|------------|
| F2-isoprostanes (F2-IsoPs) | Specific markers of lipid peroxidation | CSF | <8 days after SAH | Specific biomarker predicting delayed cerebral ischemia | Neurocrit Care. 2022;36(1):202-7. |
| F2-IsoPs | Urinary | <3 days after SAH | Increased F2-IsoP levels on day 3 after SAH were associated with development of cerebral vasospasm and worse neurologic performance after 1 month and 4 months | World Neurosurg. 2017;107:185-93. |
| Adipocyte fatty acid-binding protein (Fabp4) | Adipokine | Serum | <2 days after SAH | Elevated serum levels of Fabp4 were related to poor 3 months outcome and mortality in a cohort of patients with SAH | J Neuroinflammation. 2020;17(1):66. |
| Periostin | Matricellular proteins (MCPs) | Plasma | <3 days after SAH | One-time early-stage measurement of plasma MCPs served for reliable prediction of delayed cerebral ischemia development | Mol Neurobiol. 2019;56(10):7128-35. |
| Galectin-3 | Matricellular proteins (MCPs) | Plasma | <3 days after SAH | Biomarker for predicting subsequent development of delayed cerebral ischemia and eventual poor outcome without vasospasm. | Transl Stroke Res. 2018;9(2):110-9. |
| Osteopontin | Plasma | <3 days after SAH | Associates with higher incidence of delayed cerebral ischemia, but not angiographic vasospasm. | Neurotherapeutics. 2019;16(2):480-90. |
| Periostin | Plasma | <3 days after SAH | Higher level of periostin than patients with good outcome at 12 months. | J Clin Lab Anal. 2018;32(5):e22389. |
| Osteopontin | Plasma | <3 days after SAH | Independent predictor of poor outcome | Mol Neurobiol. 2018;55(8):6841-9. |
| Cleaved receptor for advanced glycation end products (cRAGE) | Proteolytic cleavage of full-length cell surface receptor RAGE protein | Plasma | <3 days after SAH | Highly associated with the severity and 6-month poor outcome | Clin Chim Acta. 2018;486:335-40. |
| Alpha-II spectrin breakdown products (SBDP150, SBDP145, and SBDP120) | Cytoskeletal protein | CSF | <14 days after SAH | Potential biomarkers for early recognition and severity of SAH | Sci Rep. 2018;8(1):13308. |
| Soluble Platelet-derived growth factor beta (sPDGFβ) | Shed from pericytes to CSF is related to the injury of pericytes, PDGF-βB/PDGFB signaling | CSF | <10 days after SAH | CSF sPDGFβ level increases after SAH and is higher in patients who developed cerebral vasospasm, but not for unfavorable outcome after SAH | Neurol Sci. 2018;39(6):1105-11. |
| Copeptin | Marker of endogenous vasopressin levels | Plasma | On admission | Significantly improved the predictive performance of WFNS scores | Clin Chim Acta. 2017;475:64-9. |
| Soluble Fms-like tyrosine kinase 1 (Flt-1) | Alternatively spliced transcript of the full-length domain of the VEGF-R1 | Serum | <7 days after SAH | Serum levels of sFlt-1 are increased in patients with aSAH who are at risk for severe vasospasm. | World Neurosurg. 2017;108:84-9. |
| Nesfatin-1 | Involved in central cardiovascular homeostasis | Serum | / | Serum levels of sFlt-1 are increased in patients with aSAH who are at risk for severe vasospasm. | Int J Neurosci. 2017;127(2):154-60. |

**Table 1:** Novel metabolic biomarkers for monitoring pathophysiological changes during early brain injury after SAH.
Outstanding questions
Whereas much has been learned about the pathophysiological mechanisms of SAH, neurological researchers still consider mainly early brain injury and delayed cerebral ischemia as contributors to the neurological outcomes after SAH. But the real-time metabolic changes induced by SAH are not fully understood. Current advances in spatial metabolomics and comparable proteomics might provide more precise spatial and cascade information and therapeutic targets for best translational value.

Search strategy and selection criteria
Data for this review were identified by searches of MEDLINE, Current Contents, PubMed, and references from relevant articles using the search terms “subarachnoid haemorrhage”, “early brain injury”, “delayed cerebral ischemia”, “metabolism”, “microcirculation”, “vasospasm”, “haemoglobin”, “haemolytic”, “secondary brain injury”, “neutrophil extracellular traps”, “hypoxia”, “hypoxia-inducible factor-1α”, “lactate”, “lactylation”, “mitochondria”, “metabolomic”, “proteomic”, “biomarker”, “glymphatic”, “blood-brain barrier”. Only articles published in English were included with a particular focus on the past 3 years.

Contributors
Dr. Yujie Chen and Dr. John H. Zhang conceptualized and outlined the manuscript. Dr. Yujie Chen drafted the manuscript. Dr. Ian Galea, Dr. R. Loch Macdonald, Dr. George Kwok Chu Wong, and Dr. John H. Zhang discussed contents and revised the manuscript. All authors have read and approved the current version of the manuscript.

Data sharing statement
Not Applicable.

Declaration of interests
The authors declare that they have no conflicts of interests.

Acknowledgements
This work was supported by National Natural Science Foundation of China (82030036), National Institutes of Health (R01 NS117179) and State Key Laboratory of Trauma, Burn and Combined Injury (SKLYQ202002). The funders have no roles in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

We would like to thank Dr. Jiru Zhou, Dr. Junhan Li, Dr. Jie Lin and Miss. Lin Gao for their invaluable help in designing figures in this manuscript.

References
1. Wahood W, Rizvi AA, Alexander AY, et al. Trends in admissions and outcomes for treatment of aneurysmal subarachnoid hemorrhage in the United States. Neurocrit Care. 2022;27:209–218.
2. Neifert SN, Chapman EE, Martini ML, et al. Aneurysm subarachnoid hemorrhage: the last decade. Transl Stroke Res. 2021;12(1):428–446.
3. Andersen CR, Presseau J, Saigle V, et al. Core outcomes for subarachnoid haemorrhage. Lancet Neurol. 2019;18(12):1075–1076.
4. Akeret K, Buzzi RM, Sacher CA, et al. Cerebrospinal fluid hemoglobin drives subarachnoid hemorrhage-related secondary brain injury. J Cereb Blood Flow Metab. 2021;41(11):3000–3015.
5. Zineeddine HA, Honarpisheh P, McBride D, et al. Targeting hemoglobin to reduce delayed cerebral ischemia after subarachnoid hemorrhage. Transl Stroke Res. 2022. https://doi.org/10.1007/s12975-022-00995-9. In press.
6. Fang Y, Wang X, Lu J, et al. Inhibition of caspase-1-mediated inflammatory activation reduced blood evacuation in cerebrospinal fluid after subarachnoid haemorrhage. EBioMedicine. 2022;76:101984.
7. Yu F, Saand A, Xing C, et al. CSF lipocalin-2 increases early in subarachnoid hemorrhage. Front Neurol. 2017;8:414.
8. Li Q, Ru X, Yang Y, et al. Lipocalin-2-mediated insufficient oligodendrocyte progenitor cells remyelination for white matter injury after subarachnoid hemorrhage via SC122A47 receptor/early growth response protein 1 signaling. Neurosci Bull. 2022. https://doi.org/10.1007/s11264-022-00905-w. In press.
9. Ho WM, Geoke AS, Godny B, et al. Time course of metabolomic alterations in cerebrospinal fluid after aneurysmal subarachnoid hemorrhage. Front Neurol. 2020;11:589.
10. Wang KC, Tang SC, Lee JE, et al. Cerebrospinal fluid high mobility group box 1 is associated with neuronal death in subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2017;37(3):435–444.
11. Koch M, Acharjee A, Ament Z, et al. Machine learning-driven metabolomic evaluation of cerebrospinal fluid: insights into poor outcomes after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2021;88(3):1003–1011.
12. Uhl E, Lehmberg J, Steiger HJ, Messmer K. Intraoperative detection of early microvasospasm in patients with subarachnoid hemorrhage by using orthogonal polarization spectral imaging. Neurosurgery. 2005;57(2):1307–1315, discussion 1317.
13. Naraoka M, Matsuda N, Shimamura N, Ohkuma H. Role of microcirculatory impairment in delayed cerebral ischemia and outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2022;42(1):186–196.
14. Liu H, Dienel A, Scholler K, et al. Microvasospasms after experimental subarachnoid hemorrhage do not depend on Endothelin A receptors. Stroke. 2019;50(9):2676–2686.
15. Li Q, Chen Y, Li B, et al. Hemoglobin induced NO/CGMP suppression deteriorates microcirculation via pericyte phenotype transformation after subarachnoid hemorrhage in rats. Sci Rep. 2016;6:24070.
16. Joerck A, Ritter M, Langguth N, et al. Propriodysplasias as brain degradation intermediates constrict mouse cerebral arterioles and are present in the cerebrospinal fluid of patients with subarachnoid hemorrhage. Circ Res. 2019;124(12):e1301–e1414.
17. Liu H, Schwatting J, Terpolilli NA, Nehrkorn K, Plesnilia N, Scavenging free iron reduces arteriolar microvasospasms after experimental subarachnoid hemorrhage. Stroke. 2021;52(1):4033–4042.
18. Galea I, Durnford A, Glazier J, et al. Iron deposition in the brain after aneurysmal subarachnoid hemorrhage. Stroke. 2022;53(5):1635–1642.
21 Zhou J, Guo P, Guo Z, Sun X, Chen Y, Feng H. Fluid metabolic pathways after subarachnoid hemorrhage. J Neurochem. 2022;160(1):517–531.
22 Bolatjit J, Meijers JC, Rinkel GJ, Vergouwen MD. Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review. J Cereb Blood Flow Metab. 2015;35(6):724–718.
23 Ishikawa M, Kajimura M, Morikawa T, et al. Leukocyte plugging and cortical capillary flow after subarachnoid hemorrhage. Acta Neurochir. 2018;160(9):1607–1617.
24 Zeng H, Fu X, Cai J, et al. Neutrophil extracellular traps may be a potential target for treating early brain injury in subarachnoid hemorrhage. Transl Stroke Res. 2022;13(1):112–131.
25 Zhou J, Guo P, Hao X, Sun X, Feng H, Chen Z. Neutrophil extracellular traps (NETs): a new therapeutic target for neuroinflammation and microthrombosis after subarachnoid hemorrhage? Transl Stroke Res. 2022. https://doi.org/10.1007/s12977-022-01039-y. In press.
26 Harhai Z, Bin Q, Shengzi G, et al. Neutrophil extracellular traps, released from neutrophil, promote microglia inflammation and contribute to poor outcome in subarachnoid hemorrhage. Aging. 2021;13(10):13098–13123.
27 Wu X, Zeng H, Xu C, et al. TREM4: Regulates neuroinflammatory injury by modulate proinflammatory subtype transition of microglia and formation of neutrophil extracellular traps via interaction with SYK in experimental subarachnoid hemorrhage. Front Immunol. 2021;12:7678.
28 Taran S, Trivedi V, Singh JM, English SW, McCredie VA. The use of standardized management protocols for critically ill patients with non-traumatic subarachnoid hemorrhage: a systematic review. Neurocrit Care. 2020;32(3):858–874.
29 Lu AY, Damisah EC, Winkler EA, Grant RA, Eid T, Bulsra KR. Cerebrospinal fluid untargeted metabolomic profiling of aneurysmal subarachnoid hemorrhage: an exploratory study. Br J Neurosurg. 2018;32(6):657–641.
30 Helbok R, Schieferbeck AJ, Beer R, et al. Early brain injury after aneurysmal subarachnoid hemorrhage: a multimodal neuroimaging study. Cerebrovasc Dis. 2021;52(3):150–163.
31 Ostrowski RP, Zhang JH. The insights into molecular pathways of hypoxia-inducible factor in the brain. J Neurosci. 2020;58(13):3757–3776.
32 Dong X, Li Y, Feng D, et al. Protective effect of HIF-1alpha against hypoxia reperfusion injury is mediated by modulating proinflammatory cytokines. Mol Med Rep. 2020;12(2):1281–1288.
33 Hojou D, Du Q, Yu W, Dong X, et al. 2-Methoxyestradiol alleviates neuroinflammation and brain edema in early brain injury after subarachnoid hemorrhage in rats. Front Cell Neurosci. 2022;16:896546.
34 Anan M, Nagai Y, Fukuda H, Futaki M. Lactate and lactate dehydrogenase in cerebrospinal fluid of aneurysmal subarachnoid hemorrhage. Seng Neurol Int. 2019;30(10):4451–4455.
35 Winberg J, Holm I, Cederberg D, Rundgren M, Kronvall E, Marklund N. Cerebral microdialysis-based interventions targeting delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2022;37:255–266.
36 Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2021;574(7779):579–580.
37 Yang K, Fan M, Wang X, et al. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. Cell Death Differ. 2022;29(11):1331–1406.
38 Brooks GA. Lactate as a fulcrum of metabolism. Redox Biol. 2020;35:101454.
39 Haghlara H, Shoji H, Otahi O, et al. Protein lactation induced by neural excitation. Cell Rep. 2021;32(1):109302.
40 Dicleh C, Liu H, Liu M, et al. Lactate and IL6 define separable paths of inflammatory metabolic adaptation. Sci Adv. 2021;7(16).
41 Pan L, Feng F, Wu J, et al. Demethylzylation targets lactate by inhibiting histone lactylation to suppress the tumorigenesis of liver cancer stem cells. Pharmacol Res. 2020;162:105270.
42 Pan RY, He L, Zhang J, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer’s disease. Cell Metab. 2022;23(1):414–419.
43 Enquist K, Lwen A, Hillered L, et al. CBF changes and cerebral energy metabolism during hypervolemia, hemodilution, and hypertension therapy in patients with poor-grade subarachnoid hemorrhage. J Neurosurg. 2020;123(4):675–676.
44 Wagner M, Jurcaone A, Hildebrand C, et al. Metabolic changes in patients with aneurysmal subarachnoid hemorrhage apart from perfusion deficits: neuronal mitochondrial injury? AJNR Am J Neuroradiol. 2014;35(3):551–554.
45 Chou SH, Lan J, Espósito E, et al. Extracellular mitochondria in cerebrospinal fluid and neurological recovery after subarachnoid hemorrhage. Stroke. 2017;48(8):2321–2327.
46 Youn DH, Kim BJ, Kim Y, Jeon JP. Extracellular mitochondrial dysfunction in cerebrospinal fluid of patients with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2020;23(2):422–428.
47 Zhang Z, Zhang A, Liu Y, et al. New mechanisms and targets of subarachnoid hemorrhage: a focus on mitochondria. Curr Neuropharmacol. 2022;20(7):1278–1296.
48 Chen Y, Chen Q, Sun J, Zhang L, Tan L, Feng H. Multimodal monitoring technologies for pathophysiology and management of traumatic brain injury. J Transl Crit Care Med. 2019;10(1):12–19.
49 Simonato M, Agoston DV, Brooks-Kayal A, et al. Identification of clinically relevant biomarkers of epileptogenesis - a strategic roadmap. Nat Rev Neurol. 2021;17(4):231–244.
50 Whitehouse DP, Monteiro M, Czester E, et al. Relationship of admission blood proteomic biomarkers levels to lesion type and lesion burden in traumatic brain injury: a CENTER-TBI study. Elife. 2022;10:e7777.
51 Seeley EH, Caprio ML. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci USA. 2008;105(47):18126–18131.
52 Chen Y, Hu D, Zhao L, Tang W, Li B. Unraveling metabolic alterations in transgenic mouse model of Alzheimer’s disease using MALDI MS imaging with 4–aminocinnolyl-3-carboxamid matrix. Anal Chem. 2022;104(21):39137.
53 Neumann JM, Niehaus K, Neumann N, et al. A new technological approach in diagnostic pathology: mass spectrometry imaging-based biomarkers for biomarker detection in urachal cancer. Lab Invest. 2021;101(9):1281–1288.
54 Palmer A, Papapele P, Chernyavsky I, et al. FDR-controlled metabo-lite annotation for high-resolution imaging mass spectrometry. Nat Methods. 2017;14(1):37–60.
55 Yuan Z, Zhou Q, Cai L, et al. SEAM is a spatial single nuclear metabolomics method for dissecting tissue microenvironment. Nat Methods. 2021;8(10):1223–1232.
56 Katsanos AH, Makris K, Stefani D, et al. Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage. Stroke. 2017;48(9):2386–2388.
57 Garland P, Morton M, Zolnourian A, et al. Neuroflammation light predicts neurological outcome after subarachnoid haemorrhage. Brain. 2021;144(11):761–768.
58 Helbok R, Schieferbeck A, Delazer M, et al. Cerebral tau is elevated after aneurysmal subarachnoid haemorrhage and associated with brain metabolic distress and poor functional and cognitive long-term outcome. J Neurol Neurosurg Psychiatry. 2015;86(1):79–86.
59 O’Connell GC, Alder ML, Smothers CG, Chang JHC. Large-scale informatic analysis to algorithmically identify blood biomarkers of neurological damage. Proc Natl Acad Sci USA. 2020;117(14):22764–22773.
60 Illes S. More than a drainage fluid: the role of CSF in signaling in the brain and other effects on brain tissue. Handb Clin Neurol. 2017;146:533–546.
61 Plog BA, Dashnow ML, Hitomi E, et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurol. 2015;332(5):516–526.
62 Santacruz CA, Vincent JL, Bader A, et al. Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature. Crit Care. 2021;25(1):278.
63 Edalatfar M, Piri SM, Mehrabinejad MM, et al. Biofluid biomarkers in traumatic brain injury: a systematic scoping review. Neurocrit Care. 2023;35(2):559–572.
65 Shin MK, Vazquez-Rosa E, Koh Y, et al. Reducing acetylated tau is neuroprotective in brain injury. Cell. 2021;184(10):2715-22 e223.
66 Goulay R, Flament J, Gasberti M, et al. Subarachnoid hemorrhage severely impairs brain parenchymal cerebrospinal fluid circulation in nonhuman primate. Stroke. 2017;48(8):2301–2305.
67 Golanov EV, Bovshik EI, Wong KK, et al. Subarachnoid hemorrhage - induced block of cerebrospinal fluid flow: Role of brain coagulation factor III (tissue factor). J Cereb Blood Flow Metab. 2018;38(5):793–808.
68 Thomas AJ, Ogilvy CS, Griessenauer CJ, Hanafy KA. Macrophage CD163 expression in cerebrospinal fluid: association with subarachnoid hemorrhage outcome. J Neurosurg. 2018;131(1):47–53.
69 Chen J, Wang L, Xu H, et al. Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage. Nat Commun. 2020;11(1):3159.
70 Garcia-Armengol R, Puyalto P, Missi M, et al. Cerebrospinal fluid output as a risk factor of chronic hydrocephalus after aneurysmal subarachnoid hemorrhage. World Neurosurg. 2021;154:2572–2579.
71 Scherer M, Jung JO, Cordes J, et al. Association of cerebrospinal fluid volume with cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a retrospective volumetric analysis. Neurocrit Care. 2020;33(1):152–164.
72 Ivanidze J, Ferraro RA, Giambonne AE, Segal AZ, Gupta A, Sanelli PC. Blood-brain barrier permeability in aneurysmal subarachnoid hemorrhage: correlation with clinical outcomes. AJR Am J Roentgenol. 2018;211(4):891–895.
73 Lublinsky S, Major S, Kola V, et al. Early blood-brain barrier dysfunction predicts neurological outcome following aneurysmal subarachnoid hemorrhage. EBioMedicine. 2019;45:460–472.
74 Solar P, Zamani A, Lakatosova K, Joukal M. The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments. Fluids Barriers CNS. 2022;19(1):29.
75 Garland P, Durnford AJ, Okemefuna AI, et al. Heme-hemopexin scavenging is active in the brain and associates with outcome after subarachnoid hemorrhage. Stroke. 2016;47(3):872–876.